Post-Hoc Analyses Support Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Uncontrolled Eosinophilic Asthma and Prior Exacerbations. (2025). SKIN The Journal of Cutaneous Medicine, 9(1), s524. https://doi.org/10.25251/skin.9.supp.524